Literature DB >> 21739443

Development of chronic hepatitis B virus infection in hepatitis B surface antigen negative HIV/HBV co-infected adults: a rare opportunistic illness.

Michael L Landrum1, Mollie P Roediger, Ann M Fieberg, Amy C Weintrob, Jason F Okulicz, Nancy F Crum-Cianflone, Anuradha Ganesan, Tahaniyat Lalani, Grace E Macalino, Helen M Chun.   

Abstract

Changes in serologic status in human immunodeficiency virus (HIV)/hepatitis B virus (HBV) co-infected individuals with either isolated anti-HBc or resolved HBV infection have been reported, but the frequency of clinically meaningful long-term serologic changes is not well-defined. This study therefore, examined longitudinal serologic status for hepatitis B surface antigen (HBsAg)-negative HIV/HBV co-infected participants in a large cohort. Among 5,222 cohort participants, 347 (7%) were initially isolated anti-HBc positive, and 1,073 (21%) had resolved HBV infection (concurrently reactive for anti-HBc and anti-HBs). Thirty-three (10%) of the 347 participants with isolated anti-HBc were later positive for HBsAg at least once, compared with 3 (0.3%) of those with resolved HBV (P < 0.001). A total of 14 participants became persistently positive for HBsAg and were thus classified as having late-onset chronic HBV infection at a median of 3.7 years after initial HBV diagnosis. For those initially with HBsAg-negative HIV/HBV co-infection, the rate of late-onset chronic HBV infection was 1.39/1,000 person-years. Those with late-onset chronic HBV infection experienced significant decreases in CD4 cell counts (P = 0.002) with a mean of 132 cells/µl at the time of late-onset chronic HBV infection, but no factor distinguished those who were positive for HBsAg only once from those that developed late-onset chronic HBV infection. Over a median of 2.9 years following late-onset chronic HBV infection, 3 of 14 subsequently lost HBsAg. The occurrence of late-onset chronic HBV infection in HBsAg negative HIV/HBV co-infected adults appears to be one important, albeit rare, clinical event seen almost exclusively in those with isolated anti-HBc and low CD4 cell count.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21739443     DOI: 10.1002/jmv.22155

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  4 in total

Review 1.  Hepatitis B virus vaccination in HIV-infected people: A review.

Authors:  François-Xavier Catherine; Lionel Piroth
Journal:  Hum Vaccin Immunother       Date:  2017-02-16       Impact factor: 3.452

2.  Isolated hepatitis B core antibody in HIV infected patients--can response to hepatitis B vaccine help to elucidate the cause?

Authors:  Mohammad Mahdi Majzoobi; Mojgan Mamani; Seyyed Hamid Hashemi; Hadis Gazan; Hamidreza Ghasemibasir; Mina Nikbakht; Farzaneh Esna-Ashari
Journal:  Caspian J Intern Med       Date:  2018

3.  Mortality in relation to hepatitis B virus (HBV) infection status among HIV-HBV co-infected patients in sub-Saharan Africa after immediate initiation of antiretroviral therapy.

Authors:  Amir M Mohareb; Gérard Menan Kouamé; Audrey Gabassi; Delphine Gabillard; Raoul Moh; Anani Badje; Arlette Emième; Sarah Maylin; Hervé Ménan; Emily P Hyle; Constance Delaugerre; Christine Danel; Xavier Anglaret; Karine Lacombe; Serge P Eholié; Anders Boyd
Journal:  J Viral Hepat       Date:  2021-01-23       Impact factor: 3.728

Review 4.  Isolated Anti-HBc: Significance and Management.

Authors:  Florian Moretto; François-Xavier Catherine; Clémentine Esteve; Mathieu Blot; Lionel Piroth
Journal:  J Clin Med       Date:  2020-01-11       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.